This study aims to evaluate if a 6-month course of pancrelipase (CREON) treatment improves symptoms of exocrine pancreatic insufficiency (EPI) after an attack of acute pancreatitis. Diagnosis of EPI is measured by a fecal elastase value of <200, and patients must have a qualifying symptom burden based on the EPI symptom tracker survey. Blood and stool will be analyzed as part of this study, and other surveys of health status will be used to track improvement of symptoms.

开始日期2024-02-01

申办/合作机构

The Ohio State University

[+5]

NCT01682421 / WithdrawnN/AIIT

Investigation of Treatment With Topical Corticosteroid After Posterior Lamellar Corneal Transplantation

After corneal transplantation, topical corticosteroids are used to reduce the risk of rejection.
However, the optimal postoperative treatment regimen is unknown. In most cases, a topical steroid is administered for at least 6 months after surgery, but it remains to be determined whether potent steroids offer better protection than weak steroids. Also, the length of the treatment is debated.
Since the use of steroids is not without potential serious ocular side effects, it is of considerable importance to investigate these problems.
The study aims to examine the frequency of rejection episodes after posterior lamellar keratoplasty; specifically comparing a short course of potent steroids versus a long course of weak steroids.

开始日期2012-09-01

申办/合作机构

Århus Universitetshospital

NCT01652157 / TerminatedN/A

A Long-Term Prospective Observational Safety Study of the Incidence of and Risk Factors for Fibrosing Colonopathy in US Patients With Cystic Fibrosis Treated With Pancreatic Enzyme Replacement Therapy: A Harmonized Protocol Across Sponsors(The CF-FC Study)

This is a long-term study in cystic fibrosis patients who are participating in the Cystic Fibrosis Patient Registry to assess the occurrence and risk factors for a rare bowel disorder called fibrosing colonopathy (narrowing of the large intestine). Patients will be followed at their regular clinical care visits over a 10-year period and approached if they develop symptoms of fibrosing colonopathy for collection and use of further detailed information.

开始日期2012-07-31

申办/合作机构

AbbVie, Inc.

[+4]

100 项与胰脂肪酶(Eurand) 相关的临床结果

登录后查看更多信息

100 项与胰脂肪酶(Eurand) 相关的转化医学

登录后查看更多信息

100 项与胰脂肪酶(Eurand) 相关的专利（医药）

登录后查看更多信息

101

项与胰脂肪酶(Eurand) 相关的文献（医药）

2023-09-01·Journal of substance use and addiction treatment

HIV risk perception, pre-exposure prophylaxis (PrEP) awareness, and PrEP initiation intention among women who use drugs

Article

作者: Davis, Annet ; Compton, Peggy A ; Tieu, Hong-Van ; Walcott, Melonie ; Teitelman, Anne M ; Darlington, Caroline K ; Lipsky, Rachele K ; Koblin, Beryl A

INTRODUCTION:

Women who use drugs (WWUD) are prime candidates for pre-exposure prophylaxis (PrEP) due to their elevated risk of acquiring HIV through biological, behavioral, and contextual factors. However, PrEP uptake among WWUD remains low. The relationship between unhealthy drug use and correlates of PrEP uptake in this vulnerable population is not well defined. The purpose of this study is to characterize the relationships between specific types and routes of drug use and several precursors of PrEP uptake among WWUD.

METHODS:

The study collected data via a computer-based survey from 233 women living in New York City and Philadelphia who participated in a study designed to develop and pilot a women-focused intervention for PrEP uptake. The sample of cisgender, HIV-negative women were not currently taking PrEP but considered PrEP eligible. This analysis is focused on women's HIV risk perception, PrEP awareness, PrEP initiation intention, and any use of the following drugs: barbiturates, benzodiazepines, crack cocaine, powder cocaine, hallucinogens, heroin, methamphetamines, and prescription opioids.

RESULTS:

Within the three months prior to study enrollment, 63.1 % of participants reported any drug use; 42 % reported polydrug use; 19.8 % had injected drugs; 75 % reported getting high or drunk before sex; and 44 % had been enrolled in drug treatment. Of our total sample, 41.2 % perceived themselves at risk for HIV infection, 41.6 % were aware of PrEP prior to the study, and 62.7 % intended to initiate PrEP after they were informed. When compared to other PrEP-eligible women, women who reported prescription opioid use and polydrug use perceived themselves at higher risk for HIV infection and had higher intention to start PrEP. However, they and women who reported injecting drugs also reported lower awareness of PrEP.

CONCLUSION:

These findings have implications for increasing education about PrEP and the various modes of HIV exposure to support PrEP uptake in this vulnerable population.

2023-04-01·Journal of pharmacy practice

Efficacy of a Viokace Pancreatic Enzyme Protocol for Clearing Occluded Enteral Feeding Tubes: A Quality Assurance Evaluation

Article

作者: Kurish, Heena P. ; Stumpf, Janice L. ; Bruck, Cheryl L. ; Gabriel, Jacenta M.

Background: A previous retrospective study documented restored patency to 48.2% of occluded enteral feeding tubes using alkalinized Creon pancreatic enzyme capsules. In light of the low efficacy rate, the institutional enteral feeding tube clearance protocol was subsequently revised to incorporate a newly marketed non–enteric-coated Viokace pancreatic enzyme tablet, despite the lack of published data for this indication. Objective: This study aims to evaluate the effectiveness of a Viokace-based alkalinized pancreatic enzyme protocol to clear occluded enteral feeding tubes in a university health system. Methods: This retrospective, cohort quality assurance study included adult and pediatric patients receiving a Viokace-based pancreatic enzyme protocol for enteral feeding tube occlusions in a university health system during a 12-month period. The primary outcome was effectiveness in enteral tube clearance as documented in the electronic medical record. Efficacy of the new protocol was also compared with a Creon-based alkalinized solution using historical data. Results: The Viokace protocol successfully cleared 176 of the 277 (63.5%) occluded enteral feeding tubes occurring in 205 patients included in the analysis. The revised protocol was significantly more effective at clearing occluded enteral feeding tubes ( P = 0.0056) than a protocol using Creon pancreatic enzyme capsules. Conclusion: According to this retrospective evaluation, an alkalinized Viokace pancreatic enzyme protocol was effective in clearing 63.5% of occluded enteral feeding tubes. This significantly higher success rate than previously documented with a Creon-based protocol supports the change in pancreatic enzyme formulations in the institutional protocol.

2021-12-01·Addictive behaviors reports

Associations amongst form of cocaine used (powder vs crack vs both) and HIV-related outcomes

Article

作者: Cook, Robert L ; Liu, Yiyang ; Gebru, Nioud Mulugeta ; Spencer, Emma C ; Richards, Veronica L

INTRODUCTION:

Cocaine (including powder and crack) use is common among people with HIV (PWH). We identified socio-demographic and behavioral factors associated with cocaine use (overall and various forms) among PWH; we also examined differences in HIV treatment outcomes across cocaine exposure groups.

METHODS:

The study sample (N = 1166) was derived from two cohorts of PWH in Florida between 2014 and 2020. Baseline data were linked to the Enhanced HIV/AIDS Reporting System (eHARS) which tracks HIV viral load. Socio-demographics and polysubstance use were compared by cocaine use and the three cocaine use groups (powder only n = 101, crack only n = 91, or both n = 65). The association between the three cocaine use groups, ART adherence, and HIV viral suppression (<200 copies/mL) in the following year was assessed by multivariate logistic regression.

RESULTS:

People who used cocaine had lower HIV treatment adherence and viral suppression than those who did not use. People who used powder cocaine only were more likely to be younger, Hispanic/Latinx, and employed than those who used crack only or both. Compared to people who used both powder and crack cocaine, those who used one form of cocaine had 3 + odds of having durable viral suppression in the following year.

CONCLUSION:

The dual use of both powder and crack cocaine was associated with significantly worse HIV outcomes compared to use of only one form of cocaine. Screening for powder and crack cocaine use and timely intervention are needed to improve HIV treatment outcomes among this high-risk population.

项与胰脂肪酶(Eurand) 相关的新闻（医药）

2022-07-08

·BioSpace

Report: Merck in Advanced Talks to Acquire Seagen for $40B

Merck is in late-stage discussions to acquire Seagen for about $40 billion, sources told The Wall Street Journal. Seagen is an appealing oncology target for Merck at a time when the latter is looking to bolster its cancer portfolio as mega-blockbuster Keytruda (pembrolizumab) teeters on the patent cliff. The WSJ report suggests Merck is offering more than $200 per share and hopes to close the deal on or before its quarterly earnings report on July 28. On Wednesday, Seagen’s stock closed at $175.13 per share. Rumors about the talks have been ongoing for several weeks. Seagen’s market cap is above $32 billion. In September 2020, the two companies inked a co-development pact to advance ladiratuzumab vedotin, a potential cancer therapy. Merck threw $600 million into the deal up front and acquired 5 million shares of Seagen stock for $1 billion. They also have a licensing deal for Tukysa in countries outside the U.S., Canada and Europe, for which Merck paid $125 million at the outset. Merck’s Keytruda, an anti-PD-1 checkpoint inhibitor, brought in $7.2 billion last year alone. In Q1 this year, the drug raked in $4.7 billion, up 23% from last year over the same period. Keytruda will lose exclusivity in 2028. Last year it made up 35.2% of Merck’s total revenue. Seagen’s focus is on antibody-drug conjugates (ADCs). These therapies link cancer-specific antibodies to cancer toxins. Its best-known drug is Adcetris. Merck is one of the top oncology companies in the world but doesn’t have much of a focus on ADCs. Its market cap is $233 billion. In a note to investors in June, Wells Fargo analyst Mohit Bansal wrote, “The real value to MRK (Merck) is qualitative as SEGEN (Seagen) adds durability and diversity to the company beyond Keytruda,” according to Seeking Alpha. If Merck and Seagen do close on a deal, they can expect regulators to take a close look. The U.S. Securities and Exchange Commission has increased its scrutiny of larger mergers and is taking a hard look at competing products, sometimes forcing companies to divest drugs before the deal is approved. As an example, in 2020, when AbbVie acquired Allergan, the SEC and other regulators required the companies to divest brazikumab and Zenpep (pancrelipase). If they do manage to pull the deal together, it will be the largest life science M&A activity for the year to date. So far, the largest deal has been Pfizer’s acquisition of Biohaven for $11.6 billion. It’s been a relatively quiet year, with M&A activity in the sector down 58% compared to the first half of 2021, with a valuation of $61.7 billion. In the first half of this year, there have been 137 deals, down 33% from the same period in 2021. Other deals include Bristol Myers Squibb’s acquisition of Turning Point Therapeutics for $4.1 billion, GSK's takeover of Affinavax for $3.3 billion and Biocon Biologics’ acquisition of Viatris’ biosimilar portfolio and related commercial and operational capabilities for $3.3 billion. There are numerous factors behind the slow M&A market, including ongoing supply chain problems, inflation, political uncertainty globally with the Russia-Ukraine war, and higher input costs, especially around packaging, due to inflationary pressures. Still, many biopharma companies have plenty of cash, especially if they have had any COVID-19-related products approved over the last two years. A recent PwC report noted that “pharma is in a good position to combat this issue as most companies have plenty of cash on hand and can take more risks by purchasing early-stage assets. With capital becoming harder to come by for most biotechs, pharma is in a good position to acquire many of these companies at a discount from their highs of just a couple of years ago.”

并购抗体生物类似药抗体药物偶联物

2022-06-24

·BioSpace

Merck, Seagen Talks Heat Up Under Cloud of Regulatory Scrutiny

Kena Betancur/Getty Images Talks between Merck and Seagen are heating up as the former looks to buy the latter, according to a report from The Wall Street Journal. If the merger-and-acquisition deal did go through, it would likely be a sizable one, since Seagen has a market cap above $32 billion. This follows last week’s report published by WSJ that stated Merck was exploring purchasing the biotech company. In September 2020, Merck and Seagen entered into an agreement to co-develop ladiratuzumab vedotincancer, a cancer treatment, with Merck pitching in $600 million upfront and acquiring 5 million shares of Seagen stock for $1 billion. They also have a licensing deal for Tukysa in countries outside the U.S., Canada and Europe, and Merck dropped $125 million upfront for that cancer drug. Both companies are strong players in the oncology space. Merck’s lead product is its blockbuster anti-PD-1 checkpoint inhibitor Keytruda (pembrolizumab). The drug brought in $17.2 billion in 2021 alone. In the first quarter of this year, Keytruda brought in $4.7 billion, an increase of 23% from the previous year. Seagen focuses on antibody-drug conjugates (ADCs). These drugs have onco-toxins attached to an antibody that delivers the drugs directly to the tumors. Its best-known drug is Adcetris. On June 6, Seagen and Genmab announced interim data from the innovaTV 205 trial of Tivdak (tisotumab vedotin) in combination with Keytruda in patients with recurrent or metastatic cervical cancer who have not received previous systemic therapy. The interim data demonstrated a confirmed objective response rate (ORR) of 41% and median durability of response that was not achieved within almost 19 months of median follow-up. Tivdak is an ADC made up of Genmab’s human monoclonal antibody directed to tissue factor (TF) and Seagen’s ADC technology. “With Genmab, we will continue to investigate tisotumab vedotin in combination with other therapies because there is still an unmet need for more effective first-line treatment for advanced cervical cancer patients,” Marjorie Green, M.D., senior vice president and head of late-stage development at Seagen, said in a statement. “We’re also researching innovative new tools to help increase awareness of the disparities and unmet needs that cervical cancer patients experience in order to better support this community in the future.” Although Merck is a powerhouse in the oncology space, it doesn’t really focus on ADCs. It has a significantly larger market cap than Seagen, at about $233 billion. According to Seeking Alpha, Seagen's shares have risen considerably since the WSJ report, and Wells Fargo analyst Mohit Bansal wrote in a note that the value of a deal would be within the $200-$220/share range. "The real value to MRK (Merck) is qualitative as SGEN (Seagen) adds durability and diversity to the company beyond Keytruda," Bansal said in the note obtained by Seeking Alpha. Although picking up Seagen would certainly beef up its already strong oncology portfolio, Merck is reportedly concerned that regulators might block the deal. The Securities and Exchange Commission has taken a close look at competing products with merging companies, sometimes forcing companies to divest drugs for the deals to go through. For example, in 2020, when AbbVie acquired Allergan, regulators required the companies to divest brazikumab and Zenpep (pancrelipase). A recent report on the industry by PwC notes that one of the reasons M&A activity has been so slow this year is concern over increased regulatory scrutiny. On the other hand, a driving factor for M&A interest is an increasing number of patent expirations. Although Keytruda is still growing, its patents start to expire in 2028. Keytruda has been approved for a long list of cancer indications, both as a monotherapy and in combination with numerous other cancer drugs. Amidst all of this, Seagen is undergoing some changes. In May, the company’s president, CEO and board member, Clay Siegall, resigned after domestic violence allegations, which had resulted in a leave of absence earlier in the month. The board is currently conducting a search for a replacement. Meanwhile, Roger Dansey, M.D., the company’s chief medical officer, is acting as interim CEO.

抗体抗体药物偶联物并购专利到期

2021-08-24

·Pharmaceutical Technology

Current and future players in the cystic fibrosis market

The currently available marketed drugs for cystic fibrosis (CF) target multiple aspects of the disease. Inhaled antibiotics are used for the treatment of chronic lung infections, mucolytic agents are used for reducing the viscosity of the mucus in the lungs, pancreatic enzyme replacement therapies (PERTs) are used for the treatment of CF-related exocrine pancreatic insufficiency (EPI), and CF transmembrane conductance regulator (CFTR) modulators enhance CFTR function, targeting the underlying cause of disease. The disease-modifying nature of CFTR modulators has transformed the treatment paradigm for CF over the last decade, setting a trend that is likely to persist to 2030. More than a dozen pharmaceutical companies make up the current players in the CF market (Figure). Vertex is the clear market leader, dominating the CF space with four marketed CFTR modulators available throughout the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK and Canada), including Kalydeco (ivacaftor), Orkambi (lumacaftor/ivacaftor), Symdeko/Symkevi (tezacaftor/ivacaftor and ivacaftor), and Trikafta/Kaftrio (elexacaftor, tezacaftor, ivacaftor). Since the global approval of Kalydeco in 2012, Vertex has greatly expanded the number of CF-related mutations that are eligible for CFTR modulator treatment across all age groups. Currently, Vertex’s Trikafta/Kaftrio is the world’s first triple-combination therapy for which approximately 90% of the CF population will likely be eligible. While Vertex is currently the only company with products in the CFTR modulator drug class, other players stand out with marketed products in other drug classes. Chiesi possesses two inhaled antibiotic products, Bramitob/Bethkis (tobramycin) in the US and five major European markets (5EU) (France, Germany, Italy, Spain and the UK) and Quinsair (levofloxacin) in the 5EU, as well as the mucolytic Bronchitol (mannitol) in the US and the PERT product Pertzye (pancrelipase) in the US. Two other key companies include Viatris (formerly Mylan), which owns the most widely-used inhaled antibiotic therapies, TOBI (tobramycin) and TOBI Podhaler (tobramycin inhalation powder), and Nestlé HealthScience, which owns two PERT products, Zenpep (pancrelipase) and Viokace (pancrelipase). The rest of the pharmaceutical companies with marketed drugs used for the treatment of CF include Gilead, Teva, Genentech, AbbVie, Vivus, Horizon Therapeutics and Pharmaxis. Vertex and AbbVie are the only two companies with clear stakes in both the current and future CF market. Vertex is currently pursuing label expansion for Kalydeco to CF patients ages 0 months to less than 12 months in Canada, and Trikafta/Kaftrio to pediatric CF patients ages 2-5 years in the US and 2-11 years in the 5EU and Canada. Additionally, two new products from this company are expected to launch within the next five years: VX-561 and VX-121 + tezacaftor + VX-561. Currently, AbbVie markets Creon, the most widely used PERT by CF patients. The company has two pipeline agents, ABBV-3067, a CFTR potentiator that is being studied in late-stage Phase II trials alone and in combination with galicaftor (ABBV-2222), a CFTR corrector. If successful, AbbVie will be Vertex’s first competitor in the CFTR modulator market. Laurent Pharmaceuticals is expected to be the only new player in the CF space by 2030. It is currently developing an anti-inflammatory agent, LAU-7b (fenretinide), for reducing the levels of inflammation and the severity of pulmonary infections with Pseudomonas aeruginosa. While this pipeline agent has an innovative mechanism of action and is a first-in-class drug, the company is a novice within the CF field and has not yet brought a drug to market. Due to the limited number of pipeline agents in late-stage development, GlobalData anticipates that the current players in the CF market will likely maintain their competitive positions by 2030. Related Report Cystic Fibrosis – Global Drug Forecast and Market Analysis to 2030 Get the Report Latest report from Browse over 50,000 other reports on our store. Visit GlobalData Store

First in Class

100 项与胰脂肪酶(Eurand) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	A09AA02	DB00085

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
胰腺外分泌功能不全	美国	Eurand Pharmaceuticals, Inc.	2009-08-27

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
慢性胰腺炎	临床3期	美国	Forest Laboratories LLC	2007-11-01
慢性胰腺炎	临床3期	加拿大	Forest Laboratories LLC	2007-11-01
慢性胰腺炎	临床3期	波兰	Forest Laboratories LLC	2007-11-01
慢性胰腺炎	临床3期	斯洛伐克	Forest Laboratories LLC	2007-11-01
脂肪泻	临床3期	美国	Forest Laboratories LLC	2006-11-01
囊性纤维化	临床3期	美国	Forest Laboratories LLC	2006-05-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT00880100 (CTgov)	临床3期	脂肪泻 \| 胰腺外分泌功能不全 \| 囊性纤维化	49	Ultrase® MT12	鑰壓壓鬱顧齋獵膚淵膚(簾廠淵鏇鑰廠鹹襯遞餘) = 簾鹹憲鏇製糧壓膚獵築餘觸膚鬱顧壓蓋膚鑰構 (簾製醖築網齋膚築鏇壓, 壓築鬱網鹽顧鑰遞鏇鹽 ~ 糧願艱襯範鬱糧廠製觸) 更多	-	2015-02-19
NCT01100606 (CTgov)	临床4期	囊性纤维化 \| 胰腺外分泌功能不全	15	EUR-1008 (APT-1008) (EUR-1008 (APT-1008) in Apple Juice)	範鬱憲鏇齋製膚觸鹽醖(製顧衊廠襯觸鏇鹹顧衊) = 獵獵選襯繭積繭範製願繭齋淵淵選積鹹遞膚繭 (網範鏇製餘艱鹽膚醖醖, 網願選鬱鹹鏇膚鏇簾網 ~ 獵襯齋範膚鏇遞齋觸憲) 更多	-	2014-04-10
				EUR-1008 (APT-1008) (EUR-1008 (APT-1008) in Apple Sauce)	範鬱憲鏇齋製膚觸鹽醖(製顧衊廠襯觸鏇鹹顧衊) = 夢壓積鏇獵製築廠壓膚繭齋淵淵選積鹹遞膚繭 (網範鏇製餘艱鹽膚醖醖, 淵積艱夢糧衊壓糧構製 ~ 壓襯襯夢鹽鬱簾鏇衊壓) 更多
NCT00981214 (CTgov)	临床3期	胰腺外分泌功能不全 \| 囊性纤维化	19	EUR-1008 (APT-1008)	齋鏇繭鏇獵齋廠選鹹網(憲鹹範簾夢鏇淵醖遞廠) = 壓觸範齋遞網製膚廠鹽壓遞獵觸範壓築鬱夢鬱 (蓋築鹽餘廠糧網齋築築, 壓積餘願築糧艱糧範廠 ~ 鏇餘築壓簾鹽遞觸膚鏇) 更多	-	2014-04-04
NCT00559364 (CTgov)	临床3期	慢性胰腺炎 \| 脂肪泻 \| 胰腺外分泌功能不全	50	Proton pump inhibitor (PPI)+Omeprazole	廠鑰築製築選顧鏇齋網(願醖齋製齋構繭糧積繭) = 鹽鬱築顧醖鬱獵獵築襯夢簾鑰築範鹽築願繭鑰 (艱壓願構鹹醖衊糧夢願, 構窪襯餘艱鹹築鏇餘襯 ~ 獵衊醖遞醖網憲壓醖選) 更多	-	2014-03-12
NCT00788593 (CTgov)	临床3期	慢性胰腺炎 \| 胰腺外分泌功能不全	82	EUR-1008 (APT-1008) Low Dose (EUR-1008 (APT-1008) Low Dose)	選艱鬱顧窪製繭選鬱齋(廠衊齋鏇築淵衊鹹範齋) = 鹹壓艱膚鹽網積鹽淵積範網夢廠窪糧積構築繭 (鏇襯齋繭簾製觸餘鹹鹽, 鏇醖蓋艱憲淵簾構構夢 ~ 遞觸選壓衊壓顧選齋願) 更多	-	2014-03-12
				EUR-1008 (APT-1008) High Dose (EUR-1008 (APT-1008) High Dose)	選艱鬱顧窪製繭選鬱齋(廠衊齋鏇築淵衊鹹範齋) = 廠選襯顧鹹鹽淵簾繭願範網夢廠窪糧積構築繭 (鏇襯齋繭簾製觸餘鹹鹽, 構選夢鹽構鑰積壓鏇衊 ~ 範廠鹹鏇餘製選製觸範) 更多
NCT00408317 (CTgov)	临床3期	脂肪泻 \| 囊性纤维化 \| 胰腺外分泌功能不全	36	Ultrase® MT20 (Ultrase® MT20)	願製醖鑰蓋壓膚獵繭積(糧選鏇願蓋鬱範艱網齋) = 夢構網遞夢淵範廠願鹽鑰簾積鏇廠築繭築選壓 (遞艱網艱襯淵觸築醖餘, 鑰鏇糧鏇觸醖簾廠築糧 ~ 選構鬱艱鹹遞網衊觸鹹) 更多	-	2014-03-12
				Placebo (Placebo)	願製醖鑰蓋壓膚獵繭積(糧選鏇願蓋鬱範艱網齋) = 願網糧築壓範壓廠鹽廠鑰簾積鏇廠築繭築選壓 (遞艱網艱襯淵觸築醖餘, 積鬱繭製醖獵廠觸積窪 ~ 鑰窪艱衊夢積廠艱憲遞) 更多
NCT01131507 (PR-018, CTgov)	临床4期	胰腺外分泌功能不全 \| 囊性纤维化	15	EUR-1008 (APT-1008)	齋鬱鹹鹽憲鹹簾願鬱遞(鹽襯膚網獵淵願鹹憲選) = 壓鬱醖繭淵醖夢獵獵願觸築鹽鹽願製獵蓋襯醖 (繭簾鏇簾鏇壓網遞窪選, 襯醖艱壓蓋淵醖製製遞 ~ 蓋蓋醖廠齋餘醖廠繭鹽) 更多	-	2014-03-07
Pubmed \| J Cyst Fibros	N/A	囊性纤维化	-	EUR-1008	鏇衊襯艱簾獵膚範選壓(艱鑰蓋鏇糧糧憲壓衊願) = 構醖艱鏇艱獵築廠衊鹽選襯衊襯製夢鬱夢鏇顧 (觸餘構壓膚鹽繭積齋鬱 ) 更多	-	2009-12-01
				Placebo	鏇衊襯艱簾獵膚範選壓(艱鑰蓋鏇糧糧憲壓衊願) = 觸願廠積簾餘衊鑰餘鏇選襯衊襯製夢鬱夢鏇顧 (觸餘構壓膚鹽繭積齋鬱 ) 更多